CELG-Celgene Stock Research, Ratings, and Analysis

Celgene (celg) Stock Research

Last Updated by Anonymous | Update This Page Now

►Summary | Profile | News | Chart | SWOT | Cash Flow | Comps | Buffett | WACC

Company Description: Celgene Corporation is a biopharmaceutical company engaged in the development and marketing of innovative therapies to treat cancer and immune-inflammatory related diseases, primarily in Europe and the United States. The company also creates medications for attention deficit hyperactivity disorder, psoriasis, arthritis, and fibrotic diseases, many of which are in preclinical trials. Update

Market Research Update

Health Care Industry Research & Analysis: The health care industry depends on the care of health-related services by professionals for the benefit of patients. Medical device markers, insurance companies, pharmaceutical drug developers and government institutions are major participants in the treatment of sick, injured and disabled patients. Health Care Trading Strategy: Health Care stocks tend to be less sensitive to economic changes. Look for undervalued health care investments at any point in the business cycle when stock prices are low. However, biotech, employment staffing and insurance companies may all decrease during recessions for different reasons. Government intervention is another important factor in health care investments, since government spending in health care is a very large portion of overall health care spending. When governments change spending plans, different sub-sectors in the industry are significantly affected. Upward sloping stock charts and financial news may indicate a selling opportunity while the opposite means that stocks are becoming undervalued.

Industry Sub Sector: Biotechnology. Celgene is a dominant industry leader due to its personnel, experience and financial strengths. Industry leaders are difficult to compete against, which decreases business and investor risks.

Market Challenges: Anti-Biotech protests, the policies that forbids clinical experiments, consecutive drop in stock price, and current trade war between U.S. and China. Opportunities: The increasing focus people have on the development of biotechs and lower taxes levied by China. Solutions: "Wait for it" strategy: since the trade war is turbulent and continuous variations on tariff.

Strategy Analysis Update

Strategy: Celgene has a narrow focus that serves a particular customer niche with either a unique product or with a low cost advantage over competitors. (read more). Since the market of U.S. stocks is now bearing capital dilemmas due to trade war, it is better not to invest large part of our capital to such market, given the will to earn profit in the long-run. Competitive Advantages: CLEG(Celgene) is famous for its painstaking search of clinical accuracy and acclaimed reputation; therefore, the dropping rate of CLEG is, in comparison, milder than that of other firms in the same domain(biotech).

Financial Analysis Update

Given that the worldwide turbulent of currency and trade is raging, investments in markets of international cutting-edge technologies, especially as profound as biotech, face great risks. Current Revenue Sources: Future Revenue Sources: